These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2121 related articles for article (PubMed ID: 28534943)
1. Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation. Pang L; Han S; Jiao Y; Jiang S; He X; Li P Int J Oncol; 2017 Jul; 51(1):25-38. PubMed ID: 28534943 [TBL] [Abstract][Full Text] [Related]
2. Chinese medicine Bu-Fei decoction attenuates epithelial-mesenchymal transition of non-small cell lung cancer via inhibition of transforming growth factor β1 signaling pathway in vitro and in vivo. He XR; Han SY; Li XH; Zheng WX; Pang LN; Jiang ST; Li PP J Ethnopharmacol; 2017 May; 204():45-57. PubMed ID: 28412214 [TBL] [Abstract][Full Text] [Related]
3. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways. Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082 [TBL] [Abstract][Full Text] [Related]
4. Bu-Fei decoction and modified Bu-Fei decoction inhibit the growth of non-small cell lung cancer, possibly via inhibition of apurinic/apyrimidinic endonuclease 1. Jiang ST; Han SY; Pang LN; Jiao YN; He XR; Li PP Int J Mol Med; 2018 Apr; 41(4):2128-2138. PubMed ID: 29393411 [TBL] [Abstract][Full Text] [Related]
5. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation. Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094 [No Abstract] [Full Text] [Related]
6. Modulation the crosstalk between tumor-associated macrophages and non-small cell lung cancer to inhibit tumor migration and invasion by ginsenoside Rh2. Li H; Huang N; Zhu W; Wu J; Yang X; Teng W; Tian J; Fang Z; Luo Y; Chen M; Li Y BMC Cancer; 2018 May; 18(1):579. PubMed ID: 29783929 [TBL] [Abstract][Full Text] [Related]
7. Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer. Xie C; Zhou X; Liang C; Li X; Ge M; Chen Y; Yin J; Zhu J; Zhong C J Exp Clin Cancer Res; 2021 Aug; 40(1):266. PubMed ID: 34429133 [TBL] [Abstract][Full Text] [Related]
8. PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer. Zhang X; Zeng Y; Qu Q; Zhu J; Liu Z; Ning W; Zeng H; Zhang N; Du W; Chen C; Huang JA Int J Clin Oncol; 2017 Dec; 22(6):1026-1033. PubMed ID: 28748356 [TBL] [Abstract][Full Text] [Related]
9. 13-Methyl-palmatrubine shows an anti-tumor role in non-small cell lung cancer via shifting M2 to M1 polarization of tumor macrophages. Wu Z; Zhou J; Chen F; Yu J; Li H; Li Q; Li W Int Immunopharmacol; 2022 Mar; 104():108468. PubMed ID: 35066343 [TBL] [Abstract][Full Text] [Related]
10. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling. Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778 [TBL] [Abstract][Full Text] [Related]
11. Upregulation of PD-L1 by SPP1 mediates macrophage polarization and facilitates immune escape in lung adenocarcinoma. Zhang Y; Du W; Chen Z; Xiang C Exp Cell Res; 2017 Oct; 359(2):449-457. PubMed ID: 28830685 [TBL] [Abstract][Full Text] [Related]
12. Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC). Hong W; Xue M; Jiang J; Zhang Y; Gao X J Exp Clin Cancer Res; 2020 Aug; 39(1):149. PubMed ID: 32746878 [TBL] [Abstract][Full Text] [Related]
13. Marsdenia tenacissima extract disturbs the interaction between tumor-associated macrophages and non-small cell lung cancer cells by targeting HDGF. Fu JL; Hao HF; Wang S; Jiao YN; Li PP; Han SY J Ethnopharmacol; 2022 Nov; 298():115607. PubMed ID: 35973634 [TBL] [Abstract][Full Text] [Related]
14. Tumor-associated macrophages provide a suitable microenvironment for non-small lung cancer invasion and progression. Wang R; Zhang J; Chen S; Lu M; Luo X; Yao S; Liu S; Qin Y; Chen H Lung Cancer; 2011 Nov; 74(2):188-96. PubMed ID: 21601305 [TBL] [Abstract][Full Text] [Related]
15. Tumor-associated macrophages (TAMs)-derived osteopontin (OPN) upregulates PD-L1 expression and predicts poor prognosis in non-small cell lung cancer (NSCLC). Li Y; Liu H; Zhao Y; Yue D; Chen C; Li C; Zhang Z; Wang C Thorac Cancer; 2021 Oct; 12(20):2698-2709. PubMed ID: 34423566 [TBL] [Abstract][Full Text] [Related]
16. Puerarin inhibits M2 polarization and metastasis of tumor-associated macrophages from NSCLC xenograft model via inactivating MEK/ERK 1/2 pathway. Kang H; Zhang J; Wang B; Liu M; Zhao J; Yang M; Li Y Int J Oncol; 2017 Feb; 50(2):545-554. PubMed ID: 28101568 [TBL] [Abstract][Full Text] [Related]
17. Effects of IFN-γ on the immunological microenvironment and TAM polarity in stage IA non-small cell lung cancer and its mechanisms. Zhao W; Wang H; Zhang X; Zhang L; Pu W; Ma Y; Chen W BMC Pulm Med; 2024 Jan; 24(1):46. PubMed ID: 38254043 [TBL] [Abstract][Full Text] [Related]
18. Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR Wang G; Zhao J; Zhang M; Wang Q; Chen B; Hou Y; Lu K Int J Nanomedicine; 2019; 14():4503-4515. PubMed ID: 31417255 [No Abstract] [Full Text] [Related]
19. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1. Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569 [TBL] [Abstract][Full Text] [Related]
20. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer. Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]